How does Asparlas (calaspargase pegol-mknl) compare to Oncaspar (pegaspargase)?
Asparlas is given no more frequently than every 21 days and Oncaspar is given no more frequently than every 14 days. Oncaspar is can be given intramuscularly or intravenously while Asparlas is only given intravenously.
Asparlas (calaspargase pegol-mknl) and Oncaspar (pegaspargase) are both forms of PEGylated asparaginase indicated for use in the treatment of acute lymphoblastic leukemia (ALL).
Asparlas provides for a longer interval between doses compared to Oncaspar, and has as an extended shelf life.
Asparlas (calaspargase pegol-mknl) Injection
- FDA Approved: 2018
- Dosage Interval: Asparlas is administered intravenously no more frequently than every 21 days.
- Storage: Store in refrigerator at 2°C to 8°C (36°F to 46°F).
- Unopened vials may be stored at room temperature (15°C to 25°C [59°F to 77°F]) for no more than 48 hours.
Oncaspar (pegaspargase) Injection
- FDA Approved: 1994
- Dosage Interval: Oncaspar is administered intramuscularly or intravenously no more frequently than every 14 days.
- Storage: Store in refrigerator at 2ºC to 8ºC (36°F to 46°F).
Read next
What to avoid when taking Gleevec?
Talk to your doctor about warnings, side effects, use in pregnancy and possible drug interactions with Gleevec. Take your Gleevec exactly as prescribed by your doctor. Do not use Gleevec if you are pregnant or planning a pregnancy. Take each tablet with a meal and large glass of water to help prevent stomach irritation. Do not use grapefruit products while taking Gleevec. Use caution with driving as Gleevec may cause dizziness, drowsiness or blurred vision. Continue reading
What is the survival rate of Kymriah?
Studies are ongoing to monitor the survival rate of patients who received Kymriah (tisagenlecleucel) as a cancer treatment. Currently, the available data shows the survival rate is 87.7% for patients with relapsed or refractory follicular lymphoma at 24 months after the Kymriah infusion, and 43.6% for patients with aggressive B-cell non-Hodgkin’s lymphoma. The 5-year survival rate for patients with advanced B-cell advanced B-cell acute lymphoblastic leukemia is 55%. Continue reading
How much does Tecartus cost?
Tecartus costs $373,000 as a one time CAR-T immunotherapy cancer treatment. Most people do not pay for this medicine themselves. It is a personalized medicine engineered from a patient’s own white blood cells. Costs may be covered by your insurance plan, patient assistance programs, or financial resources offered through the manufacturer. Continue reading
Related medical questions
- How does Besponsa work to treat Acute Lymphoblastic Leukemia (ALL)?
- What is the lifetime or cumulative dose for Adriamycin?
- Gleevec vs Sprycel vs Tasigna - how do they compare?
- How much does Blincyto (blinatumomab) cost?
- How long does it take Sprycel (dasatinib) to start working?
- Is there a generic for Gleevec?
- Is Sprycel a chemotherapy drug?
- How does Gleevec (imatinib) work?
- What is the cost of Kymriah?
- Is Tecartus a one-time treatment?
- Is Tasigna a form of chemotherapy?
- Is Blincyto (blinatumomab) chemotherapy?
- Can I take Gleevec while pregnant?
- How is Blincyto taken / administered?
- How is Kymriah administered?
- What type of drug is Kymriah (tisagenlecleucel)?
- What type of cancer is Daurismo (glasdegib) used to treat?
- Prednisone: What are 12 Things You Should Know?
- How long does methotrexate stay in your system?
- What is Zydelig used for and how does it work?
- What type of leukemia is Xospata (gilteritinib) used to treat?
Drug information
Related support groups
- Calaspargase Pegol (1 questions, 3 members)
- Asparlas (1 questions, 3 members)
- Pegaspargase (1 questions, 3 members)
- Oncaspar (1 questions, 5 members)
- Acute Lymphoblastic Leukemia (22 questions, 15 members)
- Leukemia (14 questions, 78 members)